Data / Form D filings / Maxona Pharmaceuticals, Inc.
Maxona Pharmaceuticals, Inc.: Form D filings
Maxona Pharmaceuticals, Inc., a pharmaceuticals company in Malvern, PA, filed 3 Form D notices with the SEC between 2021 and 2026. The latest, on August 14, 2026, reports $5.8 million sold of a $12 million offering to 56 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 101 Lindenwood Drive Suite 225, Malvern, PA, 19355
- Phone
- (484) 681-5626
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1857448
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Amendment | $12,000,000 | $5,778,673 | $6,221,327 | 56 | Jun 4, 2025 | sec.gov |
| Jun 13, 2025 | New notice | $5,000,000 | $900,163 | $4,099,837 | 15 | Jun 4, 2025 | sec.gov |
| May 5, 2021 | New notice | $10,000,000 | $5,555,000 | $4,445,000 | 34 | Apr 9, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Shahin Fatholahi | Executive Officer, Director | |
| Behshad Sheldon | Director | |
| David Nakamura | Director | |
| Richard Brand | Executive Officer |
Other pharmaceuticals companies in Pennsylvania that filed recently
- Telemachus Therapeutics, Inc. $375,000 · Oct 28, 2026
- EpiVario Inc. $185,000 · Oct 13, 2026
- PLEOPHARMA, INC. $5.5 million · Aug 10, 2026
- Duo Oncology Inc. $1.6 million · Aug 7, 2026
Every Form D from the week of Aug 10, 2026 · All recent filings in Pennsylvania · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Maxona Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.